Hypomethylating agents (HMA) are the most commonly used therapeutic intervention in chronic myelomonocytic leukemia (CMML). Due to the lack of CMML-specific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. We present the largest retrospective series of CMML (n 5 151) treated with HMA. Mean age at diagnosis was 69 years (range 50-88). According to the CMML-specific prognostic scoring system (CPSS): 17 (15%) were low- and event-free survival 14 months (95%CI: 11-17). By multivariate analysis, age < 70 years, higher levels of hemoglobin, absence of blast in peripheral blood and lower CPSS cytogenetic risk predicted for better OS. CR was significantly higher in those patients treated with decitabine (58.3%) when compared with azacitidine (20.6%) (P < .001). 13 patients (9%) received allo-SCT after a median of 4 cycles of HMA. 66 patients (50%) had HMA failure: 26 primary (34%) and 50 secondary (66%), including 35 (46%) that transformed to AML. Outcomes after HMA failure were poor with OS of 7 months (95%CI: 3-12). In conclusion, HMA are effective in CMML but new agents and combinations are needed. This data could be a benchmark for further drug development in CMML. of patients and molecular abnormalities are also common, with TET2, SRSF2, ASXL1 and RAS mutations being the most frequent.
at diagnosis make a majority of the patients unlikely candidates for transplantation. [11] [12] [13] [14] [15] Historically, HMAs were approved under the umbrella of MDS trials [16] [17] [18] and therefore, due to the lack of CMMLspecific clinical trials, the impact of these agents in the natural history of CMML is not fully understood. Most of the evidence of the impact of HMA therapy in CMML is from small studies, with reported response rates ranging from 25 to 70%, complete remission (CR) rates of 10 to 58% and median overall survival (OS) of 12 to 37 months. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] To further understand the impact of HMA based therapy on the natural history of CMML, we analyzed the single institution experience with azacitidine or decitabine in the treatment of patients with CMML.
| M E T H O D S 2.1 | Patients and methods
We retrospectively reviewed the electronic records of patients with a diagnosis of CMML treated with HMA (azacitidine or decitabine) as ini- were used to estimate the prognosis of these patients. [27] [28] [29] [30] [31] HMA was initiated at the time patients presented disease related complications such as: progressive disease with increasing blasts, complications related to cytopenias, worsening constitutional symptoms, or transfusion dependency.
| Cytogenetic analysis and target gene sequencing analysis
Routine cytogenetic analysis was conducted in the Clinical Cytogenetics laboratory at MDACC following standard protocols. Cytogenetic results were interpreted and reported according to the International System for Human Cytogenetic Nomenclature (ISCN, 2005) . 32 Baseline cytogenetic was classified into three groups: low (normal karyotype, -Y, der(3q)), intermediate (all abnormalities not in the high or low risk groups) and high (abnormalities of chromosome 7 and complex karyotypes with more than three cytogenetic abnormalities) based on the modified Spanish cytogenetic risk stratification. 7, 21, 33 Genomic DNA was extracted from whole bone marrow aspirate samples at the time of diagnosis and was subject to targeted PCRbased sequencing using a next generation sequencing (NGS) platform covering 28 or 53 genes, in patients evaluated from 2012 to 2016.
This analysis was performed at the MDACC CLIA-compliant Molecular Diagnostics Laboratory (additional details in Supporting Information).
The limit of detection for SNVs was a tumor allele frequency of at least 5%. Previously described somatic mutations registered at the 38 The majority of patients were transfusion-dependent (67%).
Therapy related CMML was present in 45 patients (30%).
Karyotype was available in 147 patients (abnormal in 103 [70%]).
According to the modified Spanish cytogenetic risk stratification, 105
(71%) belonged to the low-risk category, 27 (18%) to the intermediaterisk category, and 15 (10%) to the high-risk category.
Gene sequencing data were available in 28 patients. At least one mutation was identified among 86% of patients. The median number of mutations was 1 (range 0-3). The frequency of identified mutations included were TET2 (n 5 9, 32%), ASXL1 (n 5 6, 21%), NRAS (n 5 5,
(n 5 2, 7%), TP53 (n 5 2, 7%), BRAF (n 5 1, 4%) and KIT (n 5 1, 4% 
| Response to HMA
With a median follow up of 18 months (range 1-108), response was available in 145 patients (96%). The overall response rate (ORR) was Figure   S1A ). The median number of cycles to achieve a response was 3 (range 1-24) and the median duration of response was 9 months (range 0-68).
Twenty-two patients (15%) had stable disease without clinical benefit and 14 (10%) progressed during treatment.
In the univariate analysis, no predictors associated with CR were Figure S1B ).
| Survival
The median OS was 24 months (95% CI: 20-28), median LFS was 39 months (95% CI: 11-67), and the median EFS was 14 months (95% CI:
11-17) ( Figure 2 Table S2 ).
For patients who underwent allo-SCT, median number of cycles received before transplant was 4 (range 2-9). All patients achieved a response before transplant: 5 (38%) in CR and 8 (62%) in mCR. Median overall survival after transplant was not reached (estimated 13 months) and the cumulative incidence of treatment-related mortality (TRM) at day 100 post-transplant was 24%.
| Effect of choice of hypomethylating agent
We then studied specific outcomes in patients treated with azacitidine vs decitabine. After considering only patients treated with single agent azacitidine (n 5 35) or decitabine (n 5 73), CR as well as the combination of CR 1 mCR was significantly higher in patients treated with decitabine when compared with azacitidine (CR: 54.8% vs 23.0%, P < .001; CR 1 mCR: 77.8% vs 52.9%, P 5 .009). Although no statistical differences were observed, patients treated with decitabine had a trend toward a better ORR (81.0% vs. 67.2%, respectively; P 5 .059) and a longer OS (median 24 months vs. 20 months, P 5 .484) compared with patients treated 5-azacitidine.
To try to minimize the differences between groups, we generated a propensity score matching including hemoglobin, platelets, white were found when we generated a propensity score matching among patients treated in monotherapy (n 5 28) (Supporting Information   Table S3 ). Regarding the five patients who switched to another HMA after failure, two patients achieved mCR as best response, two patients did not achieve any response and one patient was not evaluable because he died before complete the first cycle. OS for those patients was extremely poor (median OS from failure [95% CI]: 4 months 3, 4 ).
| Cytogenetic response

| DISCUSSION
CMML is a hematopoietic stem cell disorder with both myeloproliferative and myelodysplastic features. It affects mainly elderly patients and is associated with poor outcomes. 39 The approval of HMAs for the treatment of MDS, resulted in the wide spread use of these compounds for patients with CMML, at least in the United States. However, because the clinical trials that led to the approval of these drugs
were not CMML specific, and the number of CMML patients enrolled was small (10 to 75 patients), the exact impact that HMAs have in the natural history of CMML is not well understood.
We retrospectively review the records of 151 patients treated with HMA at our Institution. It represents the largest series of CMML patients treated with HMA so far reported. The distribution of patient population was comparable with previous published studies. [22] [23] [24] [25] [26] 40 Notably, 70% of the patients in our cohort presented with a cytogenetic abnormality, clearly greater than the 30% expected in CMML patients. 7 As expected, most of them belonged to the good-risk category (71%) according to the CPSS cytogenetic risk group. Moreover, therapy-related CMML was noted in 30% of patients, a number slightly higher than the 8-16% observed in other studies. 16, 19, 21 Response was assessed with both, 2015 International Consortium Criteria for Myelodysplastic/Myeloproliferative neoplasm in adults was used to compare azacitidine vs decitabine because although we know that this response criteria have never been validated before, we considered that they are more accurate to evaluate the effect of therapy in the myeloproliferative components of the disease as leukocytosis, monocytosis or splenomegaly.
As previously published, HMA are clinically effective in the treatment of CMML patients, providing an ORR of 75% including CR rate of 41% and a OS of 20 months, comparable with other series. [19] [20] [21] [22] [23] [24] [25] 40 Clinical response was associated with a twofold increase in OS. [20] [21] [22] 25 Age < 70 years, higher levels of hemoglobin, the absence of blast in PB, as well as, low CPSS cytogenetic risk were associated with improved survival. In contrast to previous studies, no statistical differences in terms of OS were observed between the different 2016 WHO subgroups. 41, 42 Of interest, achieving a cytogenetic response with HMA did not predict for a better OS, probably due to the small number of patients with evaluable cytogenetic response and in contrast with a recent report in MDS population. 43 There has not been direct previous comparison between azacitidine and decitabine. In this analysis, CR rates were higher in patients treated with decitabine (58.3%) than 5-azacitdine (20.6%). This resulted Only thirteen patients underwent a stem cell transplant after treatment with HMA. The median number of cycles received before transplant was 4, and all underwent transplant in response. Median OS was not reached, but the cumulative incidence of TRM at day 100-post transplant is high (24%), similar to previously published data. 44 Regarding the prognostic models to estimate the risk in patients with CMML, MDAPS, CPSS and MCPS were significantly associated with OS, but only CPPS was capable to segregate the patients into the 4 groups. 45 On the other hand, IPSS seems to be a poor prognostic model for survival in patients with CMML, 29 supporting the importance of using CMML specific models.
CMML patients with HMA failure had poor outcomes with median OS of 7 months, particularly those with primary HMA failure (5 months), similar to previous reports in HMA failure in myelodysplastic syndromes. 36, 37, 46, 47 Although, relapsing with the same abnormalities observed in karyotype at diagnosis is the most frequent (76.6%), the most frequent abnormalities acquired during treatment was the trisomy 8, observed in 5% of the patients. Almost 50% of the patients relapse developing an AML, higher than previously published (22%). 37, 46 The remaining patients, relapse as a CMML, and the treatment choice was heterogeneous, including patients who received another HMA, investigational agents or allo-SCT. Switching to another HMA does not seem to be the best option in patients with HMA failure CMML, confirming the urgent need for improve salvage therapies for these patients.
Our data have several limitations. First of all, our data represent a single-institution retrospective analysis. Moreover, because we included patients with CMML diagnosed between 2004 and 2015, gene sequencing data were available only in 28 patients (platform available since 2012). However, in these patients, at least one mutation was identified among 86% of patients, similar to other published studies 8, 9 but the frequencies of the presence of different molecular alterations were slightly different with those observed from other groups. It should be noted that none of the mutations of the spliceosome components were included in the 28 or 53 NGS platform performed.
In conclusion, we present the largest series of patients with CMML treated with HMA. As previously published, HMAs has a significant activity in CMML patients, with responses associated with better outcomes. However, outcomes after HMA failure are poor, evidencing the urgency of new therapies for this type of patients.
